SCHEMBL3657147

SCHEMBL3657147

CCCCCCCC/C=C/CCCCCCCC(=O)OCCO

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 1/20 0.82
EPHX2 P34913 1/20 0.67
DGKA P23743 2/20 0.65
CNR2 P34972 2/20 0.61
MAPT P10636 2/20 0.61
ALDH1A1 P00352 1/20 0.61
THRB P10828 1/20 0.61
CNR1 P21554 1/20 0.61
TRPV1 Q8NER1 1/20 0.61
PRKCE Q02156 1/20 0.61
PRKCQ Q04759 1/20 0.61
PRKCD Q05655 1/20 0.61
PRKCA P17252 1/20 0.61
GMNN O75496 1/20 0.56
USP2 O75604 1/20 0.56
LMNA P02545 1/20 0.56
CYP1A2 P05177 1/20 0.56
POLB P06746 1/20 0.56
CYP2C9 P11712 1/20 0.56
ALOX15 P16050 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL93861 1.00 MGLL (0.82) MGLLEPHX2DGKACNR2MAPT
SCHEMBL324737 1.00 MGLL (0.82) MGLLEPHX2DGKACNR2MAPT
SCHEMBL29454638 1.00 MGLL (0.82) MGLLEPHX2DGKACNR2MAPT
SCHEMBL15664437 1.00 MGLL (0.82) MGLLEPHX2DGKACNR2MAPT
SCHEMBL15664438 1.00 MGLL (0.82) MGLLEPHX2DGKACNR2MAPT
SCHEMBL10529166 1.00 MGLL (0.82) MGLLEPHX2DGKACNR2MAPT
SCHEMBL10715660 1.00 MGLL (0.82) MGLLEPHX2DGKACNR2MAPT
SCHEMBL10491614 0.98 MGLL (0.80) MGLLEPHX2DGKACNR2MAPT
Ethylene SCHEMBL10418119 0.97 MGLL (0.78) MGLLEPHX2DGKACNR2MAPT
Ethylene SCHEMBL1564174 0.97 MGLL (0.78) MGLLEPHX2DGKACNR2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8425784-B2 Ozonolysis reactions in liquid CO2 and CO2-expanded solvents UNIVERSITY OF KANSAS (US) 2013-04-23 US claimed
US-20240207408-A1 Solid Solution Compositions and Use in Severe Pain INFIRST HEALTHCARE LIMITED (GB) 2024-06-27 US disclosed
US-11992555-B2 Solid solution compositions and use in chronic inflammation INFIRST HEALTHCARE LIMITED (GB) 2024-05-28 US disclosed
US-11918654-B2 Solid solution compositions and use in severe pain INFIRST HEALTHCARE LIMITED (GB) 2024-03-05 US disclosed
US-11844773-B2 Solid solution compositions and use in chronic inflammation INFIRST HEALTHCARE LIMITED (GB) 2023-12-19 US disclosed
US-11826428-B2 Solid solution compositions comprising cannabidiols INFIRST HEALTHCARE LIMITED (GB) 2023-11-28 US disclosed
US-11730709-B2 Compositions and methods for treating severe pain INFIRST HEALTHCARE LIMITED (GB) 2023-08-22 US disclosed
US-20220118091-A1 Solid Solution Compositions and Use in Severe Pain INFIRST HEALTHCARE LIMITED (GB) 2022-04-21 US disclosed
CN-109549927-B Solid solution compositions and their use in cardiovascular disease 因佛斯特医疗有限公司 2022-03-29 CN disclosed
US-11224659-B2 Solid solution compositions and use in severe pain INFIRST HEALTHCARE LIMITED (GB) 2022-01-18 US disclosed
US-8568563-B1 Methods of making a non-woven fire barrier mat Jonhs Manville (US) 2013-10-29 US disclosed
US-20130240781-A1 Ozonolysis Reactions in Liquid CO2 and CO2-Expanded Solvents ARCHER DANIELS MIDLAND COMPANY (US) 2013-09-19 US disclosed
US-8425784-B2 Ozonolysis reactions in liquid CO2 and CO2-expanded solvents UNIVERSITY OF KANSAS (US) 2013-04-23 US disclosed
US-20130045352-A1 NON-WOVEN FIRE BARRIER MAT JOHNS MANVILLE 2013-02-21 US disclosed
EP-2209547-A2 OZONOLYSIS REACTIONS IN LIQUID CO2 AND CO2-EXPANDED SOLVENTS University Of Kansas (US) 2010-07-28 EP disclosed
WO-2009061806-A2 OZONOLYSIS REACTIONS IN LIQUID CO2 AND CO2-EXPANDED SOLVENTS UNIVERSITY OF KANSAS (US) 2009-05-14 WO disclosed
US-20090118498-A1 OZONOLYSIS REACTIONS IN LIQUID CO2 AND CO2-EXPANDED SOLVENTS ARCHER DANIELS MIDLAND COMPANY 2009-05-07 US disclosed
US-20050101542-A1 Combination therapy for controlling appetites REGENTS OF THE UNIVERSITY OF CALIFORNIA 2005-05-12 US disclosed
WO-2004034968-A2 COMBINATION THERAPY FOR CONTROLLING APPETITES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2004-04-29 WO disclosed
US-4364743-A ESTER AND MIDDLE OIL ERNER WILLIAM E 1982-12-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101542-A1 Combination therapy for controlling appetites FAAH, FAAH2, GPR119 MGLL 12/4885EPHX2 330/4885DGKA 308/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.